| MAC | M malmoense | M xenopi | Total | ||||||||||
| RE | REH | REClari | RECipro | RE | REH | REClari | RECipro | RE | REH | REClari | RECipro | ||
| No of patients | 37 | 38 | 83 | 87 | 52 | 54 | 86 | 81 | 22 | 20 | 17 | 17 | 594 |
| Deviated from protocol | 16% | 21% | 35% | 43% | 29% | 22% | 24% | 43% | 14% | 25% | 59% | 47% | 32% |
| Deaths (all causes) | 32% | 39% | 48% | 30% | 33% | 35% | 42% | 56% | 55% | 85% | 29% | 47% | 42% |
| Deaths (due to mycobacteria) | 0% | 8% | 2% | 3% | 2% | 6% | 5% | 2% | 0% | 15% | 0% | 6% | 4% |
| Failures of treatment and relapses | 41% | 16% | 13% | 23% | 12% | 9% | 5% | 5% | 18% | 5% | 24% | 6% | 14% |
| Completed treatment as allocated, alive and cured at 5 years | 27% | 34% | 24% | 23% | 38% | 44% | 38% | 20% | 23% | 10% | 18% | 12% | 28% |
Clari, clarithromycin; Cipro, ciprofloxacin; H, isoniazid; E, ethambutol; MAC, Mycobacterium avium intracellulare; R, rifampicin.
Percentages do not always add up to 100% because some patients who died had earlier been failures of treatment or relapses.